Humana Inc. (NYSE:HUM) insider William Kevin Fleming sold 3,071 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the transaction, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Humana Inc. (HUM) opened at 253.00 on Friday. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $255.27. The stock has a market capitalization of $36.56 billion, a price-to-earnings ratio of 20.81 and a beta of 0.91. The firm’s 50-day moving average is $242.67 and its 200-day moving average is $226.49.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The business had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter last year, the firm posted $2.30 earnings per share. On average, analysts predict that Humana Inc. will post $11.55 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a yield of 0.63%. Humana’s dividend payout ratio is currently 13.06%.

COPYRIGHT VIOLATION WARNING: This article was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://theolympiareport.com/2017/08/27/william-kevin-fleming-sells-3071-shares-of-humana-inc-hum-stock.html.

Large investors have recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America boosted its stake in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares in the last quarter. Reliance Trust Co. of Delaware boosted its stake in Humana by 0.7% in the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after buying an additional 8 shares in the last quarter. Creative Planning boosted its stake in Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after buying an additional 15 shares in the last quarter. WFG Advisors LP boosted its stake in Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after buying an additional 20 shares in the last quarter. Finally, Cadence Capital Management LLC boosted its stake in Humana by 0.4% in the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after buying an additional 22 shares in the last quarter. 99.13% of the stock is owned by institutional investors and hedge funds.

HUM has been the subject of several recent research reports. UBS AG restated a “neutral” rating and set a $250.00 target price (up from $237.00) on shares of Humana in a report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Cowen and Company restated a “buy” rating and issued a $230.00 target price on shares of Humana in a report on Friday, July 14th. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $223.00 target price (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. Humana has a consensus rating of “Buy” and a consensus target price of $244.35.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.